StockData

Janux Therapeutics vs Pyxis Oncology

JANX and PYXS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How JANX and PYXS compare

Janux Therapeutics is the larger company, worth 5.5 times as much as Pyxis Oncology ($655M against $120M).

Janux Therapeutics scores higher on the StockData Score (12 against 5 for Pyxis Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricJANXPYXS
Size and price
Market cap$655M$120M
Share price$10.71$1.44
Change, 1 year−63.4%−67.0%
Change, 5 years−39.4%−88.8%
Beta (5Y)1.003.15
Employees10956
StockData Score
Total score12 (better)5
Valuation score3 (better)0
Growth score1 (better)0
Performance score2 (better)0
Health score6 (better)5
Dividend score00
Valuation
P/S27.3×–
P/B0.7× (better)10.5×
FCF yield−6.4%–
Fair value$17.10–
Margin of safety37.4%–
Growth
Revenue growth (TTM)5367%–
Profitability
Operating margin−598%–
Net margin−427%–
FCF margin−175%–
Return on equity−10.7% (better)−179%
Financial health
Debt / equity0.000.00
Current ratio16.35 (better)1.34
Altman Z-score5.03 (better)−16.21
Piotroski F-score2 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions101%40.9%
Held by insiders21.3%20.4%
Insider net buying, 12 months−$457K−$107K (better)
Short interest, % of float11.1%6.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.